Dr. Reddy’s set for March launch of affordable Ozempic generic in India; ramps up market‑priming efforts

Dr Reddy's

• Dr. Reddy’s to launch generic Ozempic injectable in India on March 21
• Prices to drop 50-60% to improve diabetes treatment affordability
• Company plans launches in over 80 markets, with Canada among earliest targets

Did our AI summary help?

Dr. Reddy’s Laboratories is gearing up to launch its generic version of semaglutide in India on March 21, positioning itself for an early mover advantage in one of the country’s largest chronic disease opportunities. The company confirmed that the first wave of approvals covers the injectable formulation of Ozempic, Novo Nordisk’s blockbuster diabetes drug, with oral and weight‑loss versions to follow.

The pharmaceutical major said it is preparing for a “competitive” pricing strategy aimed at boosting affordability and expanding access among India’s growing diabetes population. Executives reiterated that affordability remains a core pillar of Dr. Reddy’s India playbook, though they stopped short of disclosing exact price points.

Market estimates suggest generic versions of semaglutide  could enter at 50–60% below the innovator.

“We would ensure that it is a competitive pricing in the market,” said M.V. Ramana, CEO – India & Emerging Markets, when asked about where Dr. Reddy’s plans to position the drug versus Novo Nordisk’s Ozempic, at company's post earnings media call on Wednesday.

“Affordability has been something that is core to Dr. Reddy’s, so that’s the plan as we get ready to launch the product.”

Dr. Reddy’s said it is fully equipped to handle demand from day one, drawing on both in‑house facilities and contract manufacturing partners. The company is preparing manufacturing capacity for up to 12 million injectable pens annually through partner channels alone. The drug is fully developed in‑house, including the active pharmaceutical ingredient, and will also be supplied to domestic partners who will market it independently.

CEO Erez Israeli added, “we are aiming for about 12 million pens that can come from the partner in one year. And we hope that we can sell all of it or most of it.”

Executives confirmed that Dr. Reddy’s has already begun priming the market ahead of the launch. This includes deploying dedicated field forces to promote the drug, running large‑scale medical education programmes with Indian and global specialists, and building a patient‑support ecosystem to help with therapy adherence once treatment begins. The company said its promotional efforts will remain focused strictly on healthcare professionals, distancing itself from cosmetic or off‑label weight‑loss use.

Alongside the India rollout, the company is preparing for launches across more than 80 markets over the next 12 months. Canada is among the earliest target countries, with Dr. Reddy’s awaiting a decision on its regulatory submission. Approval could arrive any time between now and mid‑May, allowing the company to launch even before May if regulators clear the product early. Additional priority markets include Turkey, Brazil and several emerging markets where Dr. Reddy’s will sell both directly and through business-to-business partners.

The current approval in India covers only the injectable version for diabetes treatment. Market authorization for the oral semaglutide tablet and the Wegovy‑equivalent obesity indication will follow separately once regulatory clearances are obtained. The company said it intends to enter both oral and injectable GLP‑1 formats, reflecting global treatment trends that are expanding rapidly into obesity care.

Executives described semaglutide as one of the most significant commercial opportunities for India’s pharmaceutical sector, given rising incidence of diabetes and growing awareness around weight management therapies. The company expects the product to become a meaningful growth driver for its India business beginning FY26.

Dr. Reddy’s aims to leverage this launch as part of its broader ambition to climb into the top five pharma companies in the Indian market by the end of the decade—a target driven by a mix of innovative therapies, consumer health growth and strategic inorganic opportunities.